The use of IgG antibodies in conventional and non-conventional immunodiagnostic tests for early prognosis after treatment of Chagas disease

Journal of Immunological Methods

Volumn 370, Issue 1-2, 2011, Pages 24-34

  Wendling, Ana Paula Barbosa ^a,b   Vitelli Avelar, Danielle Marquete ^a   Sathler Avelar, Renato ^a,b   Geiger, Stefan Michael ^a   Teixeira Carvalho, Andréa ^a   Gontijo, Eliane Dias ^b   Elói Santos, Silvana Maria ^a,b   Martins Filho, Olindo Assis ^a  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

^b FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

Chagas disease; Cure assessment; Flow cytometry; Serology; Treatment; Trypanosoma cruzi

Indexed keywords

BENZNIDAZOLE; IMMUNOGLOBULIN G ANTIBODY;

ADULT; ANIMAL CELL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CHAGAS DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EPIMASTIGOTE; FEMALE; FLOW CYTOMETRY; HEMAGGLUTINATION; HEMAGGLUTINATION TEST; HUMAN; IMMUNOASSAY; IMMUNOFLUORESCENCE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; SERODIAGNOSIS; SEROLOGY; TRYPANOSOMA CRUZI; TRYPOMASTIGOTE;

ADULT; CHAGAS DISEASE; EARLY DIAGNOSIS; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; PROGNOSIS; SEROLOGIC TESTS; TRYPANOSOMA CRUZI; YOUNG ADULT;

TRYPANOSOMA CRUZI;

EID: 79960042486     PISSN: 00221759     EISSN: 18727905     Source Type: Journal    
DOI: 10.1016/j.jim.2011.05.003     Document Type: Article

References (20)

1. Camargo E.P. Growth and differentiation in Trypanosoma cruzi. I. Origin of metacyclic trypanosomes in liquid media. Rev. Inst. Med. Trop. São Paulo 1964, 6:6.
2. Cançado J.R. Criteria of Chagas disease cure. Mem. Inst. Oswaldo Cruz 1999, 94:331.
3. Cançado J.R. Long term evaluation of etiological treatment of Chagas disease with benznidazole. Rev. Inst. Med. Trop. São Paulo 2002, 44:29.
4. Cordeiro F.D., Martins-Filho O.A., Rocha M.O.C., Adad S.J., Corrêa-Oliveira R., Romanha A.J. Anti-Trypanosoma cruzi immunoglobulin G1 can be a useful tool for diagnosis and prognosis of human Chagas' disease. Clin. Diagn. Lab. Immunol. 2001, 8:112.
5. Coura J.R. Present situation and new strategies for Chagas disease chemotherapy-a proposal. Mem. Inst. Oswaldo Cruz 2009, 104:549.
6. Coura J.R., Viñas P.A. Chagas disease: a new worldwide challenge. Nature 2010, 6:6.
7. Ferreira H.O. Treatment of the undetermined form of Chagas disease with nifurtimox and benzonidazole. Rev. Soc. Bras. Med. Trop. 1990, 23:209.
8. Galvão L.M., Nunes R.M., Cancado J.R., Brener Z., Krettli A.U. Lytic antibody titre as a means of assessing cure after treatment of Chagas disease: a 10years follow-up study. Trans. R. Soc. Trop. Med. Hyg. 1993, 87:220.
9. Gomes Y.M., Lorena V.M.B., Luquetti A.O. Diagnosis of Chagas disease: what has been achieved? What remains to be done with regard to diagnosis and follow-up studies?. Mem. Inst. Oswaldo Cruz 2009, 104(Suppl. I):115.
10. Lunardelli A., Borges F.B., Mello K.F., Zeferino A.S.A. Soroprevalência da doença de Chagas em candidatos a doadores de sangue. Rev. Soc. Bras. Anal. Clin. 2007, 39:139.
11. Garcia S., Ramos C.O., Senra J.F., Vilas-Boas F., Rodrigues M.M., Campos-de-Carvalho A.C., Ribeiro-dos-Santos R., Soares M.B. Treatment with benznidazole during the chronic phase of experimental Chagas' disease decreases cardiac alterations. Antimicrob. Agents Chemother. 2005, 49:1521.
12. Laucella S.A., Mazliah D.P., Bertocchi G., Alvarez M.G., Cooley G., Viotti R., Albareda M.C., Lococo B., Postan M., Armenti A., Tarleton R.L. Changes in Trypanosoma cruzi-specific immune responses after treatment: surrogate markers of treatment efficacy. Clin. Infect. Dis. 2009, 49:1675.
13. Martins-Filho O.A., Pereira M.E.S., Carvalho J.F., Cançado J.R., Brener Z. Flow cytometry, a new approach to detect anti-live trypomastigote antibodies and monitor the efficacy of specific treatment in human Chagas' disease. Clin. Diagn. Lab. Immunol. 1995, 2:569.
14. Martins-Filho O.A., Elói-Santos S.M., Carvalho A.T., Corrêa-Oliveira R., Rassi A., Luquetti A.O., Rassi G.G., Brener Z. Double-blind study to evaluate flow cytometry analysis of anti-live trypomastigote antibodies for monitoring treatment efficacy in cases of human Chagas' disease. Clin. Diagn. Lab. Immunol. 2002, 9:1107.
15. Portela-Lindoso A.A.B., Shikanai-Yasuda M.A. Doença de Chagas crônica: do xenodiagnóstico e hemocultura à reação em cadeia da polimerase. Rev. Saúde Pública 2003, 37:107.
16. Urbina J.A. Chemotherapy of Chagas' disease: the how and the why. J. Mol. Med. 1999, 77:332.
17. Urbina J.A. Specific chemotherapy of Chagas disease: relevance, current limitations and new approaches. Acta Trop. 2010, 115:55.
18. Viotti R., Vigliano C., Armenti H., Segura E. Treatment of chronic Chagas disease with benznidazol: clinical and serological evolution of patients with long-term follow-up. Am. Heart J. 1994, 127:151.
19. Vitelli-Avelar D.M., Sathler-Avelar R., Wendling A.P.B., Rocha R.D.R., Teixeira-Carvalho A., Martins N.E., Dias J.C.P., Rassi A., Luquetti A.O., Elói-Santos S.M., Martins-Filho O.A. Non-conventional flow cytometry approaches to detect anti-Trypanosoma cruzi immunoglobulin G in the clinical laboratory. J. Immunol. Methods 2007, 318:102.
20. Weekly E.R. New global efforts to eliminate Chagas disease. Report. WER 2007, 82:259.